MedPath

A Randomized Double-blind Clinical Study for the Effect of Qingzhi Huayu Prescription on SDLDL-C/LDL-C in Patients With Coronary Heart Disease

Phase 1
Conditions
Coronary Atherosclerotic Heart Disease
Registration Number
ITMCTR1900002589
Lead Sponsor
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Objectives: patients have coronary atherosclerotic heart disease (CAD) with high sdLDL-C.
Selection criteria:
1) Age between 18 and 80 (including 18 and 80);
2) Gender is not limited;
3) Coronary angiography showed that the stenosis of any coronary artery exceeded 50%.
4) sdLDL-C (>= 52.6mg/dL)
5) Patients willing to receive atorvastatin treatment and Traditional Chinese Medicine treatment.

Exclusion Criteria

1) History of statin-related liver lesions and/or myopathy;
2) Patients with malignant tumors (excluding those cured);
3) Patients with serious diseases of heart, lung, kidney, brain and blood;
4) Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.);
5) Pregnant women and lactating women or those who have pregnancy plans and are unwilling to contracept during the study period;
6) Participate in other clinical researchers at the same time;
7) Researchers think that it is not suitable for patients to participate in this study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sdLDL-C;
Secondary Outcome Measures
NameTimeMethod
TG;HDL-C;TC;LDL-C;
© Copyright 2025. All Rights Reserved by MedPath